Nothing said here yet.
to join the conversation.
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Sell | 1,906 | $811.1K | Fri, Oct 30 |
| Chapman Steven LeonardCEO AND PRESIDENT | Sell | 3,430 | $1.5M | Wed, Oct 28 |
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Sell | 1,198 | $510.8K | Wed, Oct 28 |
| Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,162 | $495.4K | Wed, Oct 28 |
| RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER | Sell | 968 | $412.7K | Wed, Oct 28 |
| Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | Sell | 898 | $382.9K | Wed, Oct 28 |
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Sell | 865 | $369.2K | Wed, Oct 28 |
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Sell | 313 | $133.1K | Wed, Oct 28 |
| Sheena JonathanDirector | Sell | 187 | $79.7K | Wed, Oct 28 |
| Chapman Steven LeonardCEO AND PRESIDENT | Sell | 2,264 | $919.2K | Tue, Oct 27 |
| Rabinowitz MatthewEXECUTIVE CHAIRMAN | Sell | 1,718 | $697.5K | Tue, Oct 27 |
| Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,010 | $410.1K | Tue, Oct 27 |
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera has turned into one of the strongest movers in U.S. biotech in recent years, and that kind of run naturally raises a hard question for you as an investor.
Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.
Natera reported new data from the ESMO 2026 Congress and ASN Kidney Week, highlighting Signatera’s ctDNA assays across multiple cancers and expanded evidence for the Renasight genetic kidney test.
Natera (NTRA) is back in focus after new data from the ESMO Congress 2026 linked its Signatera platform to event-free survival across several cancer settings, alongside stronger reported results and fresh regulatory milestones.
Fred Alger Management, an investment management company, released its third-quarter 2026 investor letter for “Alger Capital Appreciation Fund.” The letter can be downloaded here.
Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.
NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
Testing Volume Is Growing Faster Than the Valuation Can Ignore Natera, Inc. (NASDAQ:NTRA) is turning personalized cancer monitoring into a growing clinical service, but its valuation prices in much more than today’s test volumes.